2025 Cambridge deals pass $9.25bn as AstraZeneca and Honeywell step on the gas
Major acquisitions and mega-fundraisings, mainly driven by AstraZeneca and Honeywell, have propelled the value of deals involving Cambridge-based life sciences and technology companies to more than $9.25 billion in just shy of 10 months to date in 2025.